Benjamin Burnett
Stock Analyst at Wells Fargo
(4.08)
# 994
Out of 5,182 analysts
106
Total ratings
60.49%
Success rate
10.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $175 → $177 | $142.95 | +23.82% | 4 | Mar 24, 2026 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Overweight | $34 → $30 | $23.10 | +29.87% | 1 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $37 → $43 | $34.55 | +24.46% | 4 | Feb 26, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $193 → $202 | $189.51 | +6.59% | 4 | Feb 24, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $39.56 | -11.53% | 3 | Nov 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.40 | +114.29% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $57.62 | -14.96% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $115.02 | +6.07% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $31.21 | +121.08% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $33.79 | +101.24% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $4.4 → $4.6 | $2.54 | +81.10% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $5.18 | +1,010.04% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.83 | +552.74% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $7.75 | +9,971.01% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $486 → $575 | $580.19 | -0.89% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $13 | $7.63 | +70.38% | 4 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $37.39 | +36.40% | 2 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $46 | $37.81 | +21.68% | 2 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $49 → $68 | $57.76 | +17.73% | 5 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $11.69 | +71.09% | 2 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $2.94 | +138.10% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $282 → $305 | $343.14 | -11.12% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $86 | $72.43 | +18.74% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $24.95 | +80.36% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $5.69 | +58.17% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $149.97 | -57.32% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $71.98 | +30.60% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.17 | +139.81% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $107.42 | +235.13% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.28 | +5,678.26% | 1 | Jan 6, 2021 |
Insmed
Mar 24, 2026
Maintains: Overweight
Price Target: $175 → $177
Current: $142.95
Upside: +23.82%
Amphastar Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $34 → $30
Current: $23.10
Upside: +29.87%
Alkermes
Feb 26, 2026
Maintains: Overweight
Price Target: $37 → $43
Current: $34.55
Upside: +24.46%
Axsome Therapeutics
Feb 24, 2026
Maintains: Overweight
Price Target: $193 → $202
Current: $189.51
Upside: +6.59%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $39.56
Upside: -11.53%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.40
Upside: +114.29%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $57.62
Upside: -14.96%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $115.02
Upside: +6.07%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $31.21
Upside: +121.08%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $33.79
Upside: +101.24%
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $2.54
Upside: +81.10%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $5.18
Upside: +1,010.04%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $3.83
Upside: +552.74%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $7.75
Upside: +9,971.01%
Mar 31, 2026
Maintains: Equal-Weight
Price Target: $486 → $575
Current: $580.19
Upside: -0.89%
Mar 27, 2026
Maintains: Overweight
Price Target: $27 → $13
Current: $7.63
Upside: +70.38%
Mar 23, 2026
Maintains: Overweight
Price Target: $44 → $51
Current: $37.39
Upside: +36.40%
Mar 11, 2026
Maintains: Overweight
Price Target: $43 → $46
Current: $37.81
Upside: +21.68%
Mar 10, 2026
Maintains: Overweight
Price Target: $49 → $68
Current: $57.76
Upside: +17.73%
Mar 5, 2026
Maintains: Overweight
Price Target: $23 → $20
Current: $11.69
Upside: +71.09%
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $7
Current: $2.94
Upside: +138.10%
Feb 20, 2026
Maintains: Equal-Weight
Price Target: $282 → $305
Current: $343.14
Upside: -11.12%
Feb 20, 2026
Maintains: Overweight
Price Target: $93 → $86
Current: $72.43
Upside: +18.74%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $24.95
Upside: +80.36%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.69
Upside: +58.17%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $149.97
Upside: -57.32%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $71.98
Upside: +30.60%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.17
Upside: +139.81%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $107.42
Upside: +235.13%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.28
Upside: +5,678.26%